|
WO2021064164A1
|
|
Treatment of chronic granulomatous disease
|
|
WO2021064151A1
|
|
Combination of the ethyl esters of docosahexaenoic and eicosapentaenoic acid plus vitamin d3 for prevention of age-related diseases
|
|
DE102020125497A1
|
|
Method for operating a powder jet device for dental treatment and / or implant treatment and a powder jet device
|
|
WO2021059273A2
|
|
Left atrial appendage occlusion devices
|
|
WO2021038089A1
|
|
Minimal messenger rnas and uses thereof
|
|
WO2021023896A1
|
|
Probe-induced heteroduplex mobility assay
|
|
WO2020239921A1
|
|
Apparatus for measuring optical parameters in scattering media offering increased lifetime
|
|
WO2020239920A1
|
|
Apparatus for measuring optical or physiological parameters in scattering media featuring an optical contact detector
|
|
WO2020239922A1
|
|
Optical apparatus comprising two self-calibrated optical measurement sets
|
|
WO2020234482A1
|
|
MAPKi RESISTANCE SIGNATURES
|
|
WO2020234195A1
|
|
Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
|
|
WO2020201168A1
|
|
Fc-modified biologicals for local delivery to compartments, in particular to the cns
|
|
WO2020207771A1
|
|
A method for determining the likelihood of a patient being responsive to cancer immunotherapy
|
|
WO2020152338A1
|
|
Method for selecting an illumination pattern for a fluorescence molecular tomography measurement
|
|
WO2020120668A1
|
|
Diagnosis of pseudogene-associated diseases, particularly chronic granulomatous disease
|
|
WO2020109600A1
|
|
Tuberculosis resistance prediction method
|
|
WO2020104627A1
|
|
Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
|
|
WO2020094745A1
|
|
Nelfinavir for treatment of adenoviral infection
|
|
WO2020084023A1
|
|
Portable rail system for creating sectional image recordings by means of conventional x-ray equipment
|
|
WO2020074469A1
|
|
Her2-binding tetrameric polypeptides
|
